Clear-Brain Trial

Uses

Background

Evidence quality

Highlighted claims

• The Clear-Brain study is a single-centre randomised pre-post clinical trial at Leiden University Medical Center. — Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial
• The trial tests whether low-sodium oxybate, non-invasive vagus nerve stimulation, or both can improve amyloid-beta clearance in cerebral amyloid angiopathy. — Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial
• Recruitment began with the first participant enrolled on 27 March 2025. — Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial
• The intervention phase follows a 3-month observational phase in a 6-month pre-post design. — Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial
• Participants are allocated to low-sodium oxybate, non-invasive vagus nerve stimulation, or a combination of both interventions. — Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial
• The study plans to include 60 participants split between sporadic CAA and Dutch-type hereditary CAA. — Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial